Yi‐Long Wu

机构：Xihua University, Guangdong Academy of Medical Sciences, Southern Medical University · ORCID：0000-0002-3611-0258

发表论文 2203 篇 · 总被引 114368 次 · h-index 134

代表论文

• PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (2025 · Journal of Hematology & Oncology · 被引 10)
• Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study (2025 · The Lancet Oncology · 被引 6)
• Tradeoff between information premium and institutional friction: New evidence from Regularized Government Accounting Supervision in China (2025 · The British Accounting Review · 被引 6)
• Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study (2025 · Lung Cancer · 被引 2)
• Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial (2026 · Signal Transduction and Targeted Therapy · 被引 1)
• Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer (2026 · Lung Cancer · 被引 1)